Registrant : Organisation or self-employed individual
| Name/company name: |
Genzyme Corporation |
| Acronym: |
|
| Legal status: |
Corporation
|
| Website address: |
http://www.genzyme.com
|
Sections
| Section: |
II - In-house lobbyists and trade/professional associations |
| and more precisely: |
Companies & groups |
Person with legal responsibility
| Surname, Name: |
Mr
David Meeker
|
| Position: |
CEO |
Permanent person in charge of EU relations
| Surname, Name: |
Ms
Vinciane Pirard
|
| Position: |
Director Public Affairs |
Contact details:
| Contact details of organisation's head office: |
500 Kendall Street
Cambridge MA 02142
UNITED STATES
|
| Telephone number: |
(+1) 617 252 7500 |
| Fax number: |
(+) |
| Other contact information: |
Gooimeer 10
1411DD Naarden
The Netherlands
or
Rue Guimard 15
1040 Brussels
belgium
|
Goals / remit
| Goals / remit of the organisation: |
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
|
|
The organisation's fields of interests are:
|
|
Number of persons engaged in activities falling under the scope of the Transparency Register
| Number of persons: |
2
|
|
Complementary information:
|
|
Persons accredited for access to European Parliament premises
Activities
Main EU initiatives covered the year before by activities falling under the scope of the Transparency Register:
|
To facilitate access to treatments for high, unmet medical need especially rare genetic diseases and multiple sclerosis.
To support all aspects supporting Europe’s Innovation and Research & Development activities in healthcare.
|
Fields of interest for e-mail alerts on consultations and roadmaps;
| Fields declared by the organisation: |
- Competition
- Consumer Affairs
- Economic and Financial Affairs
- Enterprise
- General and Institutional Affairs
- Internal Market
- Public Health
- Research and Technology
|
Networking
Information on (i) organisation's membership of any associations/federations/confederations or (ii) relationships to other bodies in formal or informal networks.
|
Member of BIO (US), PhARMA (US), EFPIA (EU), EBE (EU) & EuropaBio (EU)
|
Financial data
| Financial year: |
10/2011
-
10/2012
|
|
Estimated costs to the organisation directly related to representing interests to EU institutions in that year:
|
150000
€ - 200000
€
|
|
Amount and source of funding received from the EU institutions in financial year n-1 of registration
|
|
Procurement:
|
0 €
|
|
Grants:
|
0 €
|
Other (financial) information provided by the organisation:
|
|
|
